Founded in 2014, Yirdoc is a specialized developer of customized mesh nebulizer technologies for advanced inhalation drug delivery. Over the past decade, the company has focused on one clear mission: helping pharmaceutical partners improve inhalation therapy through precision-engineered aerosol delivery systems. Rather than treating the device as a standard accessory, Yirdoc views aerosol performance as an essential part of drug development strategy. Yirdoc’s core strength lies in customized mesh design for inhalation delivery. The company works to align nebulizer performance with the needs of specific formulations and therapeutic goals, supporting more effective and targeted drug delivery to the respiratory tract. This approach is especially relevant as inhalation therapies continue to expand beyond conventional respiratory products and into more complex and high-value treatment areas. In this context, device performance is no longer just a technical specification. It directly influences delivery efficiency, consistency, patient usability, and the overall development pathway of inhaled products. The company operates through a strategically structured platform that supports innovation, manufacturing, and global collaboration. Yirdoc’s R&D Center is located in Qingdao, where its engineering and development teams focus on advancing mesh nebulizer technology and improving aerosol delivery performance. Its manufacturing plant in Changsha provides the production capability needed to scale customized solutions with quality and reliability. To strengthen communication and cooperation with international partners, Yirdoc also maintains a branch office in Boston, allowing the company to stay close to the needs of the US and global pharmaceutical markets. Today, Yirdoc is supported by a team of approximately 70 engineers and specialists and generates annual revenue of around USD 15 million. This combination of technical talent, operational capability, and commercial growth reflects the company’s steady development as a focused player in inhalation drug delivery. Yirdoc is not positioned as a general device supplier. Instead, it aims to be a professional partner for pharmaceutical companies seeking tailored nebulization solutions and stronger integration between formulation and delivery technology. At ATS, Yirdoc is pleased to present its vision for the future of inhalation therapy: a future in which device design contributes directly to therapeutic success. By combining specialized mesh nebulizer technology, application-focused engineering, and a commitment to pharmaceutical innovation, Yirdoc supports the development of smarter and more effective inhalation solutions. With a foundation built on engineering expertise and a long-term focus on customized inhalation delivery, Yirdoc is committed to empowering pharmaceutical innovation through the subtle power of mesh technology.
Voiant
Voiant is the industry leading AI-based clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data. Voiant combines leadership in artificial intelligence and visionary computing, key opinion leaders for strategic therapeutic areas alignment, and clinical research experts to deliver operational excellence and consistent execution – providing the shortest path to the highest quality imaging data for clinical trials. Voiant has interpreted +1 billion images from over 700 global clinical trials, aiding numerous biopharmaceutical companies bringing new treatments to patients across oncology, respiratory, ophthalmology, cardiovascular, gastrointestinal, and liver disease domains. Voiant Hub is our built for purpose AI-powered platform, enabling us to manage the entire clinical imaging process while providing site management, as well as full transparency to sponsors every step of the way from image upload, quality control, read & analysis to delivering high quality clinical imaging endpoints.
UF Health Shands
The University of Florida’s Pulmonary, Critical Care, Lung Transplant, and Thoracic Programs form one of the nation’s premier destinations for complex lung and airway disease. As a high-volume referral center, UF provides advanced care for patients with the most challenging medical and surgical needs, including highly HLA-sensitized individuals, those requiring ECMO support, patients with multi-organ dysfunction, and adults or children needing lung or multi-organ transplantation. UF’s Pulmonary Vascular Disease Center and Rare Lung Disease Program delivers nationally recognized expertise across pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, lymphangioleiomyomatosis, and pulmonary alveolar proteinosis, each supported by accreditation as a Center of Excellence from leading national foundations. Integrated closely with thoracic surgery and cutting-edge research teams, these programs collectively drive innovation in diagnosis, therapeutics, and multidisciplinary care, establishing UF as a leading hub for advanced lung disease and transformative respiratory medicine.
Thoracent, a Maverix company
Thoracent, a Maverix company, sells airway stents and supporting products to the US medical market, including the Bonastent Airway Stent, the Micro-tech Metal Y-Stent and EBUS needles, and the Serpex Steerable Portfolio. We are committed to delivering unique, cutting-edge pulmonary products to the US medical market.
Thoracic Society of Australia and New Zealand
The Thoracic Society of Australia and New Zealand (TSANZ) is the only health peak body representing a range of professions (medical specialists, scientists, researchers, academics, nurses, physiotherapists, students and others) across various disciplines within the respiratory/sleep medicine field in Australia and New Zealand. The TSANZ is a Health Promotion Charity. TSANZ ultimate goals is to prevent respiratory illness through research and health promotion and to improve health care for people with respiratory illness.
Strados Labs
Strados Labs is a medical technology company focused on improving the lives of patients with respiratory diseases. Enabling remote monitoring of lung health, Strados Labs’ RESP Biosensor allows clinicians to continuously measure patients’ lung sounds such as cough and wheeze that can indicate an exacerbation or reduced quality of life. The technology is used to assist drug developers in demonstrating treatment efficacy in clinical trials and to support clinicians in disease surveillance and management. The RESP Biosensor is FDA-cleared, CE marked and HIPAA compliant, backed by multiple awards and clinical publications. Strados Labs is privately owned and based in Philadelphia, PA.